华恒生物正在筹划发行H股并在香港联合交易所上市

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange, aiming to enhance its global development strategy and strengthen its market position [2] Group 1 - The company aims to leverage international capital market resources and mechanisms to optimize its capital structure [2] - The move is expected to broaden financing channels and improve corporate governance and overall strength [2] - This initiative is part of the company's strategy to enhance brand influence and core competitiveness [2]